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A T cell receptor (TCR) that binds both major histocompatibility complex (MHC) class I and class II molecules
reveals a novel structural variation that can potentially allow a single TCR to have three widely differing
binding sites (Yin et al., 2011).One of the fundamental unresolved ques-
tions in immunology is whether the ab
T cell receptor (TCR) has been evolution-
arily selected to be able to interact
exclusively with major histocompatibility
complex (MHC) molecules—an idea that
can be traced back to Nils Jerne in the
era before anything was known of the
TCR and little about how MHC works
(see Huseby et al., 2004). An alternative
(though not mutually exclusive) view is
that the TCR repertoire, being more or
less randomly generated by somatic
recombination of the V(D)J elements,
can intrinsically recognize multiple types
of structure, that is, not only MHC struc-
tures, so that MHC recognition is imposed
by selection on MHC in the thymus (Van
Laethem et al., 2007). The current paper
(Yin et al., 2011, in this issue of Immunity)
is the latest in a series from the labs of
John Kappler and Philippa Marrack and
of Shaodong Dai (Huseby et al., 2005;
Dai et al., 2008; Scott-Browne et al.,
2009) that together with other recent
work (for example, Feng et al., 2007;
Garcia et al., 2009) provide strong
evidence in favor of the innate MHC reac-
tivity hypothesis.
This new study compares the structure
of a single TCR bound to both MHC
class I (MHCI) and MHCII ligands. These
structures identify an entirely unsus-
pected new level of structural flexibility
in the TCR that allows it to recognize
such widely different structures. This is
due to a previously unrecognized mecha-
nism that distorts the core variable
domain receptor.
The YAe62 TCR was isolated from
a T cell that had developed in amouse ex-
pressing I-Ab covalently linked to a single
peptide, in the absence of other MHCII-
peptide complexes or MHCI proteins(Huseby et al., 2005). It responds to I-Ab
with a known peptide (p3K) and cross-
reacts with several different MHCII mole-
cules as well as MHCI. The structure of
YAe62 bound to the MHCII I-Ab-p3K
complex was reported earlier (Dai et al.,
2008). In the current study, an artificial
MHCI-restricted peptide (pWM)was iden-
tified that acts as a ligand for YAe62 when
presented by Kb. YAe62 binds to the
MHCI Kb-pWM with an affinity within the
normal range for TCRs and approximately
half as strongly as it binds to I-Ab-p3K.
When the YAe62 TCR was crystallized
with Kb-pWMand the structure compared
to YAe62 TCR bound to I-Ab-p3K, two
major findings emerged (Yin et al., 2011).
The first is an understanding how the
individual residues of a single TCR’s
binding site interact with MHCI and
MHCII. Remarkably, the same four resi-
dues—Y46b, Y48b, and E54b from the
second complementarity determining
region (CDR2) of Vb, plus Y29a from the
CDR1 of the Va element (YAe62 has
a Va4-Vb8 TCR)—which are the main
regions of interaction with the MHCII
ligand, are also important in the interac-
tion with MHCI. These same amino acid
residues were previously found to interact
with similar regions of MHCII in other
structures of Va4-Vb8 and related TCRs
and are also important residues in interac-
tions with MHCI. They are therefore
already suspected of being conserved
MHC-contact residues (Dai et al., 2008;
Feng et al., 2007; Garcia et al., 2009;
Scott-Browne et al., 2009). These resi-
dues interact with similar regions on the
MHCI and MHCII molecules, the CDR2b
residues with the I-Ab and Kb a1 helices,
and Y28a with the I-Ab b1 and Kb a2
helices. There are differences in the posi-
tions of individual side chains of CDRImmuresidues in the two structures, and some
movement of the main chain of CDR3,
which is to be expected to accommodate
the structural differences between the
two ligands. These will not be described
here, but it is interesting that three of the
four conserved interaction residues for
both MHCI and MHCII are tyrosines. The
aromatic rings of Y29a and Y48b both lie
flat on the a helices of each MHC mole-
cule, interacting with regions of the MHC
a helices where there are no bulky side
chains, though Y46b’s position in both
structures in relation to the position of
Y48b suggests that its major role might
be to stabilize the position of Y48b.
When an alanine scan mutagenesis was
performed on the YAe62 TCR, all four of
these residues were found to be crucial
for the ability to bind both I-Ab-p3K and
Kb-pWM tetramers. Indeed, the majority
of the residues in CDR1b and CDR2b
whose mutation to alanine reduced
tetramer binding are shared between the
MHCI and MHCII ligands.
The second major finding, and the one
that is the most exciting for its wide impli-
cations, is that in binding to Kb-pWM, the
TCR undergoes a structural realignment
of two of the b strands that form the Va-
Ja-region junction. Effectively, in the class
I-bound structure, the CDR3a’s support
posts split apart at the level of the canon-
ical J region FGXG motif such that the
bulk of the Va-domain containing the
CDR1a and CDR2a rotates away from
the CDR3a. A variable domain of immuno-
globulin or TCR has a b-barrel structure,
made up from a total of nine antiparallel
b strands. CDR1 is the loop between
strands 4 and 5, CDR2 is the loop
between strands 6 and 7, and CDR3 is
the loop between strand 8 (representing
the C-terminal end of the V region, Va innity 35, July 22, 2011 ª2011 Elsevier Inc. 1
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Figure 1. Three Different Conformers of TCR
This schematic illustrates how three different conformers can be made from the same TCR. The closed conformer is the structure that has been most often
encountered in TCRs, whether bound to ligand or free. In this issue of Immunity, Yin et al. (2011) identify two variant structures where a rotation in the J region
of the V domain swings the CDR1 and CDR2 out and away from the other chain’s CDRs. The open conformers were found to exist in both Va and Vb domains.
They rotate the CDR1 andCDR2 by 8 to 12 relative to their position in the closed conformer. This results inmovement of individual residues in the tip of the CDRs
by about 4 A˚. In the representation of the open conformers, the positions of CDRs in the closed conformer are shown in paler hues.
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Previewsthis case) and strand 9 (the J region, Ja).
In the novel ‘‘open’’ conformer identified
by Yin et al. (2011), b strands 8 and 9 are
separated such that the CDR1 and 2 of
Va are pushed about 4 A˚ away from the
CDR3 and therefore from the b chain’s
CDRs (Figure 1). Structurally, this occurs
by strand 9 separating from the bonds it
normally makes with strand 8 and rotating
away from it. In the open structure,
b strand 9 rotates outwards at G102a
(the second glycine residue of the FGXG
motif), and the open structure is stabilized
by rotation of another side chain (Q97a) to
form new hydrogen bonds between the
strands near the CDR3 loop.
In theYAe62TCR, this structural change
occurs in the Va domain upon binding to
MHCI but has the standard ‘‘closed’’
configuration when bound to MHCII. Yin
and colleagues analyzed the database of
TCR structures and found that the open
structure also occurs in human TCRs
with Va4 (bound to MHCI or unliganded)
and in an MHCI-bound mouse TCR with
Vb2 (Yin et al., 2011). All of the hVa4 struc-
tures show the open conformation, but
none are available where hVa4 is bound
toMHCII. PotentiallyMHCII-binding could
induce (or require) alteration to the stan-
dard closed configuration, although Yin
et al. (2011) argue that an unusual amino2 Immunity 35, July 22, 2011 ª2011 Elsevieracid substitution at the end of the hVa4
region could disrupt the normal hydrogen
bonding between b strands 8 and 9 and
thus favor the open conformer to be the
standard for hVa4-utilizing TCRs. For the
mVb2, three MHCI-bound structures
involving one particular TCR, plus the
unbound form of a second TCR, show
the closed configuration of b strands 8
and 9. However, the bound form of this
second mVb2 TCR (KB5-20) shows the
open conformer. One important caveat
for this TCR is that its CDR3b is extremely
long and has to undergo a radical confor-
mational change to flatten it to allow the
TCR to even approach its MHCI ligand
(Reiser et al., 2002). Thus in this case, the
opening of b strands 8 and 9 could be
a result of the CDR3b conformational
change rather than important in its own
right. However, as Yin et al. (2011) argue,
the structure is remarkably similar to that
of YAe62 bound to Kb-pWM, and YAe62
has a very short CDR3b.
The fascinating implication of these
findings is that rotation of the CDR1 and
2 away from the CDR3 can happen for
either chain, or not, resulting in three
significantly different TCR conformers. A
fourth would be possible if this were to
happen in both chains. This would allow
an individual TCR to interact with signifi-Inc.cantly different ligands. This has funda-
mental implications for increasing the
diversity of the TCR repertoire and helps
explain the cross-reactivity of individual
TCRs on different MHC allelic products
(as well as MHCI and MHCII) as well as
to unrelated peptides presented on the
same or different MHC molecules.
When the genes for the TCR were
cloned more than 25 years ago, many
of us expected that the secret of
T cell MHC-restriction in general, and of
restricted recognition of MHCI or MHCII,
would be revealed in the sequences of
the V domains. But despite certain prefer-
ences for MHCI or MHCII attributable
to CDR1 and CDR2 sequence differences
within Va families (Sim et al., 1998), this
was not the case. Similarly, the initial
structural analyses of TCR-MHC com-
plexes did not reveal the rules for MHC
restriction and class specificity. The
discovery of multiple structures of an indi-
vidual TCR (Yin et al., 2011) can help
explain why the correlation of sequence
or even structure to the fundamental
biology has been so difficult. Yet at the
same time, the structures of the MHCI-
and MHCII-bound forms of YAe62
TCR also reveal definable patterns in the
TCR residues that are important for the
interactions with both MHCI and MHCII.
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PreviewsClearly it will be important to try to find
more examples of these different con-
formers of TCR Va or Vb in TCRs binding
to different ligands in order to gauge the
relevance of the open conformers to TCR
specificity and repertoire.
TCR repertoire generation has never
before been accused of thriftiness. The
potential of a T cell to get three different
binding structures out of a single TCR
shows that the profligacy of a T cell’s
misspent thymic youth—when many
TCRs are tried out, but most are either
dangerous or useless—can be amelio-
rated in the T cell’s maturity by making
the best use of the options that are left.REFERENCES
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Unc93B1, a multitransmembrane ER-resident protein, controls intracellular trafficking of endosomal Toll-like
receptors. In this issue of Immunity, Fukui et al. (2011) revealed that Unc93B1 regulates differential transport
of TLR7 and TLR9 into signaling endosomes to prevent autoimmunity.Endosomal Toll-like receptors (TLRs)
recognize viral nucleic acids and induce
activation of antiviral genes. Upon endo-
cytosis of virions, TLR9 binds to double-
stranded DNA (dsDNA) rich in unmethy-
lated CpG motifs found in DNA viruses,
and TLR7 recognizes single-stranded
RNA (ssRNA) with GU-rich sequences
found in viral RNA. However, such
molecular patterns associated with viral
nucleic acids are not necessarily unique
to viruses, because mammalian nucleic
acids also share features that are recog-
nized by these TLRs. Under certain
circumstances, self nucleic acids can
accidentally enter the endosome and
trigger TLR7 and TLR9, which can lead
to autoimmune diseases including psori-
asis, arthritis, and systemic lupus erythe-
matosus (SLE) (Marshak-Rothstein and
Rifkin, 2007). The innate immune system
has in place multiple regulatory mecha-nisms to prevent recognition of self
nucleic acids. One such mechanism in-
volves regulation of TLR intracellular
trafficking. At steady state, the majority
of TLR7 and TLR9 are expressed in the
endoplasmic reticulum (ER) (Figure 1).
Upon viral infection or TLR signaling,
TLR7 and TLR9 are mobilized to traffic
from the ER to the endosomes where viral
recognition takes place. A multitrans-
membrane protein found in the ER at
steady state, Unc93B1, controls traffick-
ing of all endosomal TLRs, TLR3, 7, 8,
and 9 (Kim et al., 2008). Subcellular local-
ization of TLR7andTLR9 is regulated such
that these receptors are confined to the
endosomes and are excluded from the
plasma membrane, where self nucleic
acids are accessible. An additional level
of control is provided by the fact that
TLR7 and TLR9 are active only once they
are cleaved in the acidified ‘‘signalingendosomes’’ by endosomal proteases
(Figure 1; Barton and Kagan, 2009).
Once within the signaling endosomal
compartment, TLR9 and TLR7 recruit the
adaptor proteinMyD88 and trigger signals
leading to inflammatory cytokine expres-
sion through NF-kB activation. These
receptors are further transported to lyso-
some-related organelle by the adaptor
protein-3 (AP-3) complex, enabling them
to recruit interferon regulatory factor-7
(IRF7) and activate transcription of type I
interferon (IFN) genes (Sasai et al., 2010).
However, how the relative distribution of
TLR7 and TLR9 in the signaling endo-
somes within the same responding cell is
coordinated has remained unclear.
The current study by Fukui et al. (2011)
builds on their previous finding that
TLR9 competes with TLR7 for Unc93B1-
dependent transportation to signaling
endosomes (Fukui et al., 2009) andnity 35, July 22, 2011 ª2011 Elsevier Inc. 3
